Protara Therapeutics (TARA) Shares Outstanding (Diluted Average) (2021 - 2026)

Protara Therapeutics' Shares Outstanding (Diluted Average) history runs 6 years deep, the most recent figure standing at $57.5 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Diluted Average) rose 41.35% year-over-year to $57.5 million; the TTM figure through Mar 2026 stood at $57.5 million (up 41.35% YoY), while the FY2025 annual figure was $42.8 million, up 108.01% from the prior year.
• Shares Outstanding (Diluted Average) was $57.5 million for Q1 2026 at Protara Therapeutics, up from $42.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $57.5 million in Q1 2026 to a low of $11.3 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $22.7 million across 5 years, with a median of $11.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Diluted Average) advanced 0.18% in 2022, then soared 256.43% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $11.3 million in 2022, then advanced by 0.64% to $11.3 million in 2023, then jumped by 81.73% to $20.6 million in 2024, then jumped by 108.01% to $42.8 million in 2025, then jumped by 34.32% to $57.5 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $57.5 million (Q1 2026), $42.8 million (Q4 2025), and $42.3 million (Q3 2025), per Business Quant data.